Dr. Stephen B. Ruddy Ph.D. is the Sr. VP & Chief Technical Officer at Deciphera Pharmaceuticals Inc.
As the Sr. VP & Chief Technical Officer of Deciphera Pharmaceuticals Inc, the total compensation of Dr D at Deciphera Pharmaceuticals Inc is $601,540. There are 13 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Dr D is 57, he's been the Sr. VP & Chief Technical Officer of Deciphera Pharmaceuticals Inc since . There are 12 older and 8 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Stephen's mailing address filed with the SEC is 500 Totten Pond Road, 6th Floor, Waltham, MA 02451, United States.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: